Keros Therapeutics, Inc. Common Stock

KROS XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

210M

Short interest (May 15)

8.6%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.48%

↑ 11.2%

Available Shares

↓ 6.3%

Price Chart

Company Overview

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001664710

Asset Type: CS

Market Data

Market Cap: $208,803,880

Employees: 87

Status: Active

Short Interest

Current Borrow Fee 0.48%

Range: 0.42% - 0.55%

Available Shares 1M

Range: 1.1M - 1.3M

Recent Changes

Fee Change: ↑ 7.7%

Available Change: ↑ 4.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime